Here are relevant reports on : education-administration-market
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027
The global companion animal pharmaceuticals market in terms of revenue was estimated to be worth $14.4 billion in 2022 and is poised to reach $19.6 billion by 2027, growing at a CAGR of 6.3% from 2022 to 2027. Major players operating in the market Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK) are some of the market players.
- Published: March 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Injectable Drug Delivery Market by Product (Device, Autoinjectors, Formulation, Suspensions, Nanoparticles), Site of Administration (Dermal, Organ), Formulation Packaging (Ampoules, Vials), Usage Pattern (Curative, Immunization) - Forecast to 2031
The Asia Pacific injectable drug delivery market, valued at US$161.32 billion in 2025, stood at US$176.96 billion in 2026 and is projected to advance at a resilient CAGR of 9.8% from 2026 to 2031, culminating in a forecasted valuation of US$282.22 billion by the end of the period. The growth of the Asia Pacific injectable drug delivery market is driven by the increasing incorporation of biologics, biosimilars, and long-acting injectables, alongside a rapidly growing patient population and an escalating burden of chronic diseases across major countries in the region.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Identity Governance and Administration Market by Component (Solution and Services), Deployment Type, Organization Size, Industry Vertical (BFSI, Government and Defense, and Telecom and IT), and Region - Global Forecast to 2023
The global identity governance and administration market size is expected to grow from USD 3.8 billion in 2018 to USD 7.7 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 15.2% during the forecast period. Major growth drivers for the market include such as globalization and rise in regulatory compliances. Major vendors offering the identity governance and administration solution across the globe include Oracle (US), IBM (US), SailPoint (US), SAP (Germany), Microsoft (US), CA Technologies (US), Evidian (France), NetIQ (US), One Identity (US), RSA Security (US), Hitachi ID (Canada), Saviynt (US), AlertEnterprise (US), Omada (Denmark), and SecureAuth (US).
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Europe Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]- Forecast to 2031
The Europe Pharmaceutical drug delivery market, valued at USD501.62 billion in 2025, stood at USD519.62 billion in 2026 and is projected to advance at a resilient CAGR of 6.2% from 2026 to 2031, culminating in a forecasted valuation of USD703.19 billion by the end of the period. The market growth is driven by rising use of biologics and biosimilars, an increasing prevalence of chronic diseases, and growing acceptance of innovative drug delivery devices, including auto-injectors, prefilled syringes, and inhalation systems.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031
The US injectable drug delivery market, valued at US$285.81 billion in 2025, stood at US$309.90 billion in 2026 and is projected to advance at a resilient CAGR of 8.5% from 2026 to 2031, culminating in a forecasted valuation of US$465.15 billion by the end of the period. The growth of the veterinary contract manufacturing & research market is driven by the increasing adoption of biologics and long-acting injectables, rising demand for patient-centric and self-administration delivery systems, and the need for advanced formulation, device engineering, and scalable manufacturing capabilities.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Europe Contrast Media Market by Product (Microbubble, Iodine, Gadolinium, Barium-based), Modality (CT, MRI, Ultrasound), Indication (Cancer, GIT, CVD, Musculoskeletal, Neurology, Urology), Route of Administration (IV, Oral), End User - Forecast to 2031
The Europe contrast media market is projected to reach USD 3.19 billion by 2031, growing at a CAGR of 7.5% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Elastomeric Pumps Market by Product (Continuous Rate, Variable Rate), Treatment (Chemotherapy, Antibiotic, Iron Chelation Therapy), Administration Route (Intravenous, Subcutaneous), End User (Hospital, Ambulatory Surgery Center) - Global Forecast to 2022
The global elastomeric pumps market is expected to reach USD 592.0 Million by 2022 from USD 432.1 Million in 2017, growing at a CAGR of 6.5% from 2017 to 2022. Increasing number of surgeries, wide usage in treatment, rising incidence of chronic diseases, and increasing adoption for disposable infusion pumps, are some of the major driving factors driving the growth of the global elastomeric pumps market. However, the high cost of treatment and challenges in reimbursement are hindering the growth of this market to a certain extent.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Vascular Access Device Market Type [Central, Peripheral (Venous {PIVC, Midline}, Arterial), Intraosseous], Route of Insertion, Application [Chemotherapy, Fluid Administration, Diagnostic], End User [Hospital (Public, Private)] - Global Forecast to 2031
The global vascular access device market is projected to reach USD 8.70 billion by 2031, growing at a CAGR of 6.7% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: February 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
